These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Abatacept as add-on therapy for rheumatoid arthritis. Allison C Issues Emerg Health Technol; 2005 Sep; (73):1-4. PubMed ID: 16317826 [TBL] [Abstract][Full Text] [Related]
8. A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis. Barr C J Infus Nurs; 2007; 30(2):96-104; quiz 120. PubMed ID: 17413494 [TBL] [Abstract][Full Text] [Related]
9. [Abatacept in the treatment of active rheumatoid arthritis]. Nielsen H; Hansen A Ugeskr Laeger; 2009 Jan; 171(4):214-7. PubMed ID: 19174034 [TBL] [Abstract][Full Text] [Related]
11. [Effect of CTLA4-Ig on radiographic outcome of patients with rheumatoid arthritis]. Harigai M Clin Calcium; 2007 Apr; 17(4):577-84. PubMed ID: 17404488 [TBL] [Abstract][Full Text] [Related]
12. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus. Sherrer Y Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608 [TBL] [Abstract][Full Text] [Related]
13. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Ruderman EM; Pope RM Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145 [TBL] [Abstract][Full Text] [Related]
14. Abatacept management during the perioperative period in patients with rheumatoid arthritis: report on eight orthopaedic procedures. Nishida K; Nasu Y; Hashizume K; Nakahara R; Ozawa M; Harada R; Machida T; Ozaki T Mod Rheumatol; 2014 May; 24(3):544-5. PubMed ID: 24506697 [No Abstract] [Full Text] [Related]
15. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists. Scheinfeld N J Dermatolog Treat; 2006; 17(4):229-34. PubMed ID: 16971318 [TBL] [Abstract][Full Text] [Related]
17. [Selective inhibition of T-cell activation with fusion protein CTLA4lg as a new treatment option for rheumatoid arthritis]. Krüger K Z Rheumatol; 2005 Feb; 64(1):40-1. PubMed ID: 15756499 [No Abstract] [Full Text] [Related]
18. T-cell agents in the treatment of rheumatoid arthritis. Solomon GE Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis. Tsao NW; Shojania K; Marra CA Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):9-18. PubMed ID: 24325566 [TBL] [Abstract][Full Text] [Related]
20. Reduced numbers of circulating CD28-negative CD4+ cells in patients with rheumatoid arthritis chronically treated with abatacept. Gómez-García L; Ramírez-Assad C; Vargas A; Massó F; Sánchez-Muñoz F; Márquez-Velasco R; Amezcua-Guerra LM; Bojalil R Int J Rheum Dis; 2013 Aug; 16(4):469-71. PubMed ID: 23992270 [No Abstract] [Full Text] [Related] [Next] [New Search]